MC2TCN
  • Nanotech & Cancer Treatment

    Nanotech & Cancer Treatment

    People of the Center
    The people who make The Center what it is today.
    Collaborations
    Our collaborations with other related organizations.
    Our Facilities
    The facilities at the Center.
    Research Areas
    Research areas at the Center.
  • Research Projects
  • Resources

    Resources

    Publications
    Publications by our leaders and staff.
    Clinical Trials
    Clinical Trials related to our Research Projects.
    Seminars & Events
    Seminars & Events related to our work.
    FAQ
    Frequently asked questions about the Center.
    News
    News related to the Center and our work.
  • Contact Us
  1. Home
  2. Nanotech & Cancer Treatment
  3. Research Areas

Research Areas

Ongoing Center research projects have 4 critical objectives:

Novel Ultrasmall Silica-Organic Hybrid Nanoparticles

Research will aim to design and advance a novel suite of modular sub-10 nanometer silica-organic hybrid nanoparticles in water-based environments with tunable size, brightness, and geometry as translatable platforms for diagnostic and/or therapeutic applications. Design and new functionalities of these nanoparticles will be informed by the results of ongoing Center projects and previously completed studies.

Image-Guided Surgery using Novel Optically-driven Ultrasmall Particle Platform and Real-time Handheld Device Technologies

Research will seek to achieve more expedient and reliable localization, staging, and treatment of metastatic melanoma in the intraoperative setting. Additionally, research in this realm will seek to reduce attendant surgical risks using fluorescence-based, real-time multiplexed detection tools. These optical tools enable simultaneous identification of critical cancer and/or normal tissue targets.

Novel Ultrasmall Targeted Particle Therapeutics

Research will seek to develop sub 10-nm particle-based therapeutic delivery platforms designed to carry small molecule inhibitors or radiotherapeutic labels. These platforms will be designed to either target specific genetic and molecular alterations that contribute to disease progression or be selectively retained at the target site for enhanced tumor cell kill. Innovative designs will be implemented and optimized to enhance tumor-directed delivery, accumulation, and efficacy while effectively eliminating dose-limiting toxicity.

Biomarkers

Research will seek to identify an ensemble of reliable predictive and prognostic biomarkers that require validation in prospective clinical trials with an emphasis on cancer staging and tumor response to particle therapies.

Partners

  • Memorial Sloan Kettering Cancer Center
  • Cornell University
  • National Cancer Institute

MC2TCN PODCAST

Listen to our latest podcast series.

Keep Up To Date

  • FAQ
  • Privacy & Terms
  • Sitemap
  • © 2017 MSK-Cornell Center for Translations of Cancer Nanomedicine
  • New York Web Design by Avatar New York